Clinical trials, read closely
Retatrutide, trial by trial: what the Phase 1b, Phase 2 and Phase 3 evidence for retatrutide actually measured.
A physician-adjacent reading of the published record on this investigational triple-agonist — the endpoints, the doses studied, and the questions the trials have not yet answered — with every number walked back to its source.
The short version
Retatrutide is an experimental medicine being studied for weight loss and type 2 diabetes. It is a single molecule that switches on three of the body's own hormone signals at once — GLP-1, GIP, and glucagon — which is why scientists call it a triple agonist (one key that fits three locks). In plain terms, it quiets appetite and helps the body burn more energy, and in trials people lost a large amount of weight. In one 48-week study, the highest dose led to about a 24% drop in body weight [1]. It is given as a once-a-week shot under the skin. Retatrutide is still investigational — not approved by the FDA — so everyone who has taken it did so inside a clinical trial. Side effects were mostly stomach-related, such as nausea, plus a small rise in heart rate; what people report, including the downsides, is on the page for reported effects and safety. This site reads the trial record study by study and explains, in plain language, what each one actually measured.
What does retatrutide do
Retatrutide activates the GLP-1, GIP, and glucagon receptors with one engineered peptide [3]. The GLP-1 and GIP arms lower appetite and sharpen glucose-dependent insulin release; the glucagon arm adds energy expenditure and helps the liver mobilize fat [6]. Stacking all three signals is the design idea: earlier medicines in this class hit one or two of these receptors, and the trials to date suggest the third arm is what pushes the weight-loss numbers higher than dual- or single-receptor agents have reached [6]. A 2025 review frames the roughly 24% weight loss seen at the top Phase 2 dose over 48 weeks as a step-change over prior incretin therapies [6].
Practically, the receptors do different jobs. The GLP-1 and GIP receptors are incretin receptors — they respond to gut hormones released after eating, amplifying insulin only when blood sugar is elevated, which is why the class rarely causes lows on its own [2]. The glucagon receptor is the unusual addition: glucagon normally raises blood sugar, but at controlled agonist levels it nudges the body to spend more energy and clear fat from the liver, an effect visible in the fatty-liver substudy where liver fat fell by more than 80% [5]. The molecule itself is a 39-amino-acid peptide carrying a fatty-acid tail that keeps it circulating for about a week [4]. None of this is a treatment instruction — it is a description of what the published pharmacology and trials report about an investigational compound.
What the trials have measured so far
The trial record is unusually deep for a drug still in development. The first-in-human Phase 1b study established an elimination half-life of about six days — the pharmacokinetic basis for once-weekly dosing — and the highest-dose group lost 8.96 kg more than placebo over 12 weeks [4]. The 48-week Phase 2 obesity trial then reported a mean body-weight change of -24.2% at 12 mg once weekly versus -2.1% with placebo [1]. In type 2 diabetes, a 36-week Phase 2 trial lowered HbA1c (a three-month blood-sugar marker) by 2.02 percentage points at 24 weeks and reduced body weight by 16.94% at 36 weeks, both at 12 mg [2]. A Phase 2a substudy in fatty liver disease cut liver fat by 82.4% at 24 weeks, with 86% of participants reaching a normal liver-fat level [5]. A 2025 meta-analysis of three randomized trials (878 patients) pooled the weight effect at a mean -14.33% versus placebo [13]. The trial-by-trial breakdown lives on the page for retatrutide results across the trials, and the head-to-head framing on retatrutide vs tirzepatide.
Where retatrutide sits among incretin therapies
Retatrutide belongs to the incretin family — the same broad class as the gut-hormone-based medicines that have reshaped obesity and diabetes care over the past decade. What sets it apart is the number of receptors it engages. Single agonists act on one receptor; dual agonists act on two; retatrutide is a triple agonist, adding the glucagon receptor to the GLP-1 and GIP targets [3][8]. A 2026 review of the field describes a steadily expanding armamentarium of single, dual, and triple agonists now being tested across obesity and cardio-kidney-liver-metabolic disease, with retatrutide among the most-watched triple agents [8]. The practical significance is that each added receptor is a bet on a larger or broader effect — and, potentially, a different side-effect profile. Retatrutide's Phase 2 weight numbers are the largest reported in the class to date [1][6], but larger numbers in separate trials are not the same as proven superiority, which is why the head-to-head comparison is treated carefully on retatrutide vs tirzepatide. The honest summary: a promising design with striking early data and pivotal trials still to report [7].
How this reading is organized
This reading is organized the way a clinician skims a file. The mechanism — the triple-receptor mechanism of action — sits with the key studies on the research page. The efficacy readouts, endpoint by endpoint, sit on the results page. The dose ranges studied and the half-life and pharmacokinetics sit on the dosage page, framed strictly as research context, never as a recommended dose. Reader questions are answered plainly in the frequently asked questions about retatrutide, and every quantitative claim on the site traces to the full reference list.
Two cautions frame everything here. First, retatrutide is investigational: as of 2026 it is in Phase 3 trials and is not approved by the FDA or any regulator, so all of the figures come from studies, not from a label [1][6]. Second, the largest numbers come from Phase 2 trials of a few hundred people; the pivotal Phase 3 program — obesity, diabetes, and dedicated cardiovascular and kidney-outcome trials — is still running and has not reported [7]. The through-line is discipline: numbers are attributed to the study that produced them, reviews and registrations are labeled as such, and the compound's unapproved status is kept in plain view rather than buried in a footnote.